These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37549559)

  • 1. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
    Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
    Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
    Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
    Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
    J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.
    Kuhle J; Barro C; Disanto G; Mathias A; Soneson C; Bonnier G; Yaldizli Ö; Regeniter A; Derfuss T; Canales M; Schluep M; Du Pasquier R; Krueger G; Granziera C
    Mult Scler; 2016 Oct; 22(12):1550-1559. PubMed ID: 26754800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
    Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
    Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
    Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
    Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
    Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microstructural and functional brain abnormalities in multiple sclerosis predicted by osteopontin and neurofilament light.
    Orsi G; Cseh T; Hayden Z; Perlaki G; Nagy SA; Giyab O; Olsen DA; Madsen JS; Berki T; Illes Z
    Mult Scler Relat Disord; 2021 Jun; 51():102923. PubMed ID: 33813096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
    Yeo T; Bayuangga H; Augusto-Oliveira M; Sealey M; Claridge TDW; Tanner R; Leppert D; Palace J; Kuhle J; Probert F; Anthony DC
    J Neuroinflammation; 2022 Oct; 19(1):252. PubMed ID: 36210459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients.
    Midaglia L; Rovira A; Miró B; Río J; Fissolo N; Castilló J; Sánchez A; Montalban X; Comabella M
    Eur J Neurol; 2024 Jan; 31(1):e16077. PubMed ID: 37754568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.
    Camara-Lemarroy C; Metz L; Kuhle J; Leppert D; Willemse E; Li DK; Traboulsee A; Greenfield J; Cerchiaro G; Silva C; Yong VW
    Mult Scler; 2022 Nov; 28(13):2081-2089. PubMed ID: 35848622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis.
    Ercan Z; Bilek F; Demir CF
    Mult Scler Relat Disord; 2021 Oct; 55():103219. PubMed ID: 34433118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS.
    Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F
    Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.